157 related articles for article (PubMed ID: 37953489)
21. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?
Bhanvadia V; Shet T; Rao V; Epari S; Gujral S; Jain H; Bagal B; Sengar M
Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624
[TBL] [Abstract][Full Text] [Related]
22. [Clinical analysis of 30 cases of Castleman disease with different types of thoracic involvement].
Zhang XX; Jiang L; Wang CY; Gu YY; Li LG; Xia TT; Huang Y; Huang PK; Zhang QL
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):149-156. PubMed ID: 32135633
[No Abstract] [Full Text] [Related]
23. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
24. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
26. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
27. The full spectrum of Castleman disease: 273 patients studied over 20 years.
Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
[TBL] [Abstract][Full Text] [Related]
28. Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
Newman SK; Jayanthan RK; Mitchell GW; Carreras Tartak JA; Croglio MP; Suarez A; Liu AY; Razzo BM; Oyeniran E; Ruth JR; Fajgenbaum DC
Yale J Biol Med; 2015 Dec; 88(4):383-8. PubMed ID: 26604862
[TBL] [Abstract][Full Text] [Related]
29. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
[TBL] [Abstract][Full Text] [Related]
31. Castleman disease.
Carbone A; Borok M; Damania B; Gloghini A; Polizzotto MN; Jayanthan RK; Fajgenbaum DC; Bower M
Nat Rev Dis Primers; 2021 Nov; 7(1):84. PubMed ID: 34824298
[TBL] [Abstract][Full Text] [Related]
32. Unicentric Castleman disease: A case report of an atypical presentation and successful management.
Muhammad T; Alkheder A; Mazloum A; Almooay A; Naziha L; Shaheen M
Int J Surg Case Rep; 2024 May; 118():109688. PubMed ID: 38669805
[TBL] [Abstract][Full Text] [Related]
33. Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980.
Takeuchi K
J Clin Exp Hematop; 2022; 62(2):79-84. PubMed ID: 35768240
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review.
Fayand A; Boutboul D; Galicier L; Kahn JE; Buob D; Boffa JJ; Cez A; Oksenhendler E; Grateau G; Ducharme-Bénard S; Georgin-Lavialle S
Amyloid; 2019 Dec; 26(4):197-202. PubMed ID: 31364863
[No Abstract] [Full Text] [Related]
35. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
36. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
[TBL] [Abstract][Full Text] [Related]
37. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
38. Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital.
Luo JM; Li S; Huang H; Cao J; Xu K; Bi YL; Feng RE; Huang C; Qin YZ; Xu ZJ; Xiao Y
BMC Pulm Med; 2015 Apr; 15():34. PubMed ID: 25886851
[TBL] [Abstract][Full Text] [Related]
39. Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China.
Guo M; Nong L; Wang M; Zhang Y; Wang L; Sun Y; Wang Q; Liu H; Ou J; Cen X; Ren H; Dong Y
Ann Hematol; 2024 Jan; 103(1):153-162. PubMed ID: 37749319
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
